Yağ Asidi Oksidasyon ve Karnitin Metabolizma Bozukluklar
Özet
Mitokondriyal yağ asit β-oksidasyonu ve karnitin metabolizması, özellikle açlık ve stres dönemlerinde vücudun enerji dengesini korumak için kritik bir rol oynar. Bu yolağın enzimlerinde meydana gelen genetik bozukluklar, enerji üretiminde aksamalara yol açarak hipoglisemi, miyopati ve kardiyomiyopati gibi çeşitli klinik tablolara neden olabilir. Tanı genellikle açilkarnitin profili ve genetik analizlerle konulurken, tedavi stratejileri temel olarak uzun süreli açlıktan kaçınma ve diyet düzenlemeleri üzerine kuruludur.
Mitochondrial fatty acid β-oxidation and carnitine metabolism play a critical role in maintaining the body's energy balance, especially during periods of fasting and stress. Genetic disorders affecting the enzymes in this pathway disrupt energy production, leading to various clinical conditions such as hypoglycemia, myopathy, and cardiomyopathy. While diagnosis typically relies on acylcarnitine profiling and genetic analysis, therapeutic strategies are primarily focused on avoiding prolonged fasting and implementing specific dietary management.
Referanslar
Rinaldo P, Matern D, Bennett MJ. Fatty acid oxidation disorders. Annu Rev Physiol. 2002; 64:477-502.
Eaton S, Bartlett K, Pourfarzam M. Mammalian mitochondrial beta-oxidation. Biochem J. 1996;320 (Pt 2):345-357.
Morris AAM, Spiekerkoetter U. Disorders of Mitochondrial Fatty Acid Oxidation and Riboflavin Metabolism. Saudubray JM, Matthias RB, Walter J. (Eds). Inborn Metabolic Diseases Diagnosis and Treatment. 6th ed. Heidelberg: Springer; 2016. p.201-213.
Gregersen N, Rhead W, Christensen E. Riboflavin responsive glutaric aciduria type II. Prog Clin Biol Res. 1990; 321:477-494.
American College of Medical Genetics Newborn Screening Expert Group. Newborn screening: toward a uniform screening panel and system--executive summary. Pediatrics. 2006;117(5 Pt 2): S296-S307.
El-Gharbawy A, Vockley J. Inborn Errors of Metabolism with Myopathy: Defects of Fatty Acid Oxidation and the Carnitine Shuttle System. Pediatr Clin North Am. 2018;65(2):317-335.
Roe CR, Ding J. Mitochondrial fatty acid oxidation disorders. In: Metabolic and Molecular Bases of Inherited Disease, Scriver CR, Sly WS, Childs B, et al (Eds), McGraw-Hill, New York 2001. p.2297.
Bonnet D, Martin D, Pascale De Lonlay, et al. Arrhythmias and conduction defects as presenting symptoms of fatty acid oxidation disorders in children. Circulation 1999; 100:2248-2253.
Ibdah JA, Bennett MJ, Rinaldo P, et al. A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women. N Engl J Med 1999; 340:1723-1731.
Merritt JW II, Chang IJ. Medium-chain acyl-coenzyme A dehydrogenase deficiency. In: Adam MP, Ardinger HH, Pagon RA, et al, GeneReviews [Internet], University of Washington, Seattle, 2000 (updated 2019).
Linder M, Hoffmann GF, Matern D. Newborn screening for disorders of fatty-acid oxidation: Experience and recommendations from an expert meeting. J Inherit Metab Dis 2010; 33:521-526.
Sun A, Merritt JW II. Orphan drugs in development for long-chain fatty acid oxidation disorders: Challenges and progress. Orph Drug Res Rev 2015; 5:33-41.
Sharma S, Black SM. Carnitine homeostasis, mitochondrial function, and cardiovascular disease. Drug Discov Today Dis Mech 2009;6:1–4.
Jeukendrup AE, Saris WH, Wagenmakers AJ. Fat metabolism during exercise: a review—part II: regulation of metabolism and the effects of training. Int J Sports Med 1998;19:293–302.
Byers SL, Ficicioglu C. The infant with cardiomyopathy: when to suspect inborn errors of metabolism? World J Cardiol 2014;26:1149–55.
Tang NLS, Ganapathy V, Wu X, et al. Mutations of OCTN2, an organic cation/carnitine transporter, lead to a deficient cellular carnitine uptake in primary carnitine deficiency. Hum Mol Genet 1999;8:655–660.
Tein I. Carnitine transport: pathophysiology and metabolism of known molecular defects. J Inherit Metab Dis. 2003;26(2-3):147-169.
Rinaldo P, Stanley CA, Hsu BYL, et al. Sudden neonatal death in carnitine transporter deficiency. J Pediatr 1997;131:304–5.
Stanley CA, DeLeeuw S, Coates PM, et al. Chronic cardiomyopathy and weakness or acute coma in children with a defect in carnitine uptake. Ann Neurol 1991;30:709–16.
Lamhonwah AM, Olpin SE, Pollitt RJ, et al. Novel OCTN2 mutations: no genotype–phenotype correlations: early carnitine therapy prevents cardiomyopathy. Am J Med Genet 2002;111:271–284.
Rijlaarsdam RS, van Spronsen FJ, Bink-Boelkens MTHE, et al. Ventricular fibrillation without overt cardiomyopathy as first presentation of organic cation transporter 2 deficiency in adolescence. Pacing Clin Electrophysiol 2004;27:675–676.
Longo N, di San Filipo CA, Pasquali M. Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C Semin Med Genet 2006;142C:77–85.
Bremer J, Buist NRM. Carnitine-metabolism and functions. Physiol Rev 1983;63: 1420–80.
Silva MFB, Aires CCP, Luis PBM, et al. Valproic acid metabolism and its effect on mitochondrial fatty acid oxidation: a review. J Inherit Metab Dis 2008;31:205–16.
Baruteau J, Sachs P, Broué P, et al. Clinical and biological features at diagnosis in mitochondrial fatty acid beta-oxidation defects: a French pediatric study of 187 patients. J Inherit Metab Dis. 2013;36(5):795-803.
Vitoria I, Martín-Hernández E, Peña-Quintana L, et al. Carnitine-acylcarnitine translocase deficiency: experience with four cases in Spain and review of the literature. JIMD Rep. 2015;20:11-20.
Rubio-Gozalbo ME, Vos P, Forget PP, et al. Carnitine-acylcarnitine translocase deficiency: case report and review of the literature. Acta Paediatr. 2003;92(4):501-504.
Ventura FV, Costa CG, Struys EA, et al. Quantitative acylcarnitine profiling in fibroblasts using [U-13C] palmitic acid: an improved tool for the diagnosis of fatty acid oxidation defects. Clin Chim Acta. 1999;281(1-2):1-17.
Knottnerus SJG, Bleeker JC, Wüst RCI, et al. Disorders of mitochondrial long-chain fatty acid oxidation and the carnitine shuttle. Rev Endocr Metab Disord. 2018;19(1):93-106.
Vockley J, Charrow J, Ganesh J, et al. Triheptanoin treatment in patients with pediatric cardiomyopathy associated with long chain-fatty acid oxidation disorders. Mol Genet Metab 2016;119:223–31.
Al Aqeel AI, Rashed MS, Wanders RJA. Carnitine-acylcarnitine translocase deficiency is a treatable disease. J Inherit Metab Dis 1999;22:271–5.
Bougnères PF, Saudubray JM, Marsac C, et al. Fasting hypoglycemia resulting from hepatic carnitine palmitoyl transferase deficiency. J Pediatr. 1981;98(5):742-746.
Demaugre F, Bonnefont JP, Mitchell G, et al. Hepatic and muscular presentations of carnitine palmitoyl transferase deficiency: two distinct entities. Pediatr Res. 1988;24(3):308–11.
Vianey-Saban C, Mousson B, Bertrand C, et al. Carnitine palmitoyl transferase I deficiency presenting as a Reye-like syndrome without hypoglycaemia. Eur J Pediatr. 1993;152(4):334-338.
Bergman AJ, Donckerwolcke RA, Duran M, et al. Rate-dependent distal renal tubular acidosis and carnitine palmitoyltransferase I deficiency. Pediatr Res. 1994;36(5):582-588.
Korman SH, Waterham HR, Gutman A, et al. Novel metabolic and molecular findings in hepatic carnitine palmitoyltransferase I deficiency. Mol Genet Metab. 2005;86(3):337-343.
Innes AM, Seargeant LE, Balachandra K, et al. Hepatic carnitine palmitoyltransferase I deficiency presenting as maternal illness in pregnancy. Pediatr Res. 2000;47(1):43-45.
Borch L, Lund AM, Wibrand F, et al. Normal Levels of Plasma Free Carnitine and Acylcarnitines in Follow-Up Samples from a Presymptomatic Case of Carnitine Palmitoyl Transferase 1 (CPT1) Deficiency Detected Through Newborn Screening in Denmark. JIMD Rep. 2012;3:11-15.
Stanley CA, Sunaryo F, Hale DE, et al. Elevated plasma carnitine in the hepatic form of carnitine palmitoyltransferase-1 deficiency. J Inherit Metab Dis. 1992;15(5):785-789.
Sinclair GB, Collins S, Popescu O, et al. Carnitine palmitoyltransferase I and sudden unexpected infant death in British Columbia First Nations. Pediatrics. 2012;130(5):e1162-e1169.
Thuillier L, Rostane H, Droin V, et al. Correlation between genotype, metabolic data and clinical presentation in carnitine palmitoyl transferase 2 (CPT2) deficiency. Hum Mutat 2003;21:493–501.
Deschauer M, Wieser T, Zierz S. Muscle carnitine palmitoyltransferase II deficiency: clinical and molecular genetic features and diagnostic aspects. Arch Neurol 2005;62:37–41.
Isackson PJ, Bennett MJ, Lichter-Konecki U, et al. CPT2 gene mutations resulting in lethal neonatal or severe infantile carnitine palmitoyl transferase II deficiency. Mol Genet Metab 2008;94:422–7.
Vladutiu GD. The molecular diagnosis of metabolic myopathies. Neurol Clin 2000; 18:53–104.
Wieser T, Deschauer M, Olek K, et al. Carnitine palmitoyltransferase II deficiency: molecular and biochemical analysis of 32 patients. Neurology 2003;60:1351–3.
Smith EC, El-Gharbawy A, Koeberl DD. Metabolic myopathies: clinical features and diagnostic approach. Rheum Dis Clin North Am 2011;37:2201–17.
Gillingham MB, Scott B, Elliott D, et al. Metabolic control during exercise with and without medium-chain triglycerides (MCT) in children with long-chain 3 hydroxyl acyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency. Mol Genet Metab 2006;89:58– 63.
Huerta-Alardín AL, Varon J, Marik PE. Bench-to-bedside review: rhabdomyolysis – an overview for clinicians. Crit Care 2005;9:158–69.
Vianey-Saban C, Divry P, Brivet M, et al. Mitochondrial very-long-chain acyl-coenzyme A dehydrogenase deficiency: clinical characteristics and diagnostic considerations in 30 patients. Clin Chim Acta 1998;269:43–62.
Boneh A, Andresen BS, Gregersen N, et al. VLCAD deficiency: pitfalls in newborn screening and confirmation of diagnosis by mutation analysis. Mol Genet Metab 2006;88:166–70.
McHugh DM, Cameron CA, Abdenur JE, et al. Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: a worldwide collaborative project. Genet Med 2011;13:230–54.
Solis JO, Singh RH. Management of fatty acid oxidation disorders: a survey of current treatment strategies. J Am Diet Assoc 2002;102:1800–3.
Spiekerkoetter U, Lindner M, Santer M, et al. Treatment recommendations in longchain fatty acid oxidation defects: consensus from a workshop. J Inherit Metab Dis 2009;32:498–505.
Das AM, Illsinger S, Lücke T, et al. Isolated mitochondrial long-chain ketoacyl-CoA thiolase deficiency resulting from mutations in the HADHB gene. Clin Chem. 2006;52(3):530-534.
Saudubray JM, Martin D, de Lonlay P, et al. Recognition and management of fatty acid oxidation defects: a series of 107 patients. J Inherit Metab Dis. 1999;22(4):488-502.
den Boer ME, Dionisi-Vici C, Chakrapani A, et al. Mitochondrial trifunctional protein deficiency: a severe fatty acid oxidation disorder with cardiac and neurologic involvement. J Pediatr. 2003;142(6):684-689.
den Boer ME, Wanders RJ, Morris AA, et al. Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: clinical presentation and follow-up of 50 patients. Pediatrics. 2002;109(1):99-104.
Tyni T, Pihko H, Kivelä T. Ophthalmic pathology in long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency caused by the G1528C mutation. Curr Eye Res. 1998;17(6):551-559.
Boese EA, Jain N, Jia Y, et al. Characterization of Chorioretinopathy Associated with Mitochondrial Trifunctional Protein Disorders: Long-Term Follow-up of 21 Cases. Ophthalmology. 2016;123(10):2183-2195.
Dionisi-Vici C, Garavaglia B, Burlina AB, et al. Hypoparathyroidism in mitochondrial trifunctional protein deficiency. J Pediatr. 1996;129(1):159-162.
Tyni T, Rapola J, Palotie A, et al. Hypoparathyroidism in a patient with long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency caused by the G1528C mutation. J Pediatr. 1997;131(5):766-768.
Wilcken B, Leung KC, Hammond J, et al. Pregnancy and fetal long-chain 3-hydroxyacyl coenzyme A dehydrogenase deficiency. Lancet. 1993;341(8842):407-408.
Tyni T, Ekholm E, Pihko H. Pregnancy complications are frequent in long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency. Am J Obstet Gynecol. 1998;178(3):603-608.
Sperk A, Mueller M, Spiekerkoetter U. Outcome in six patients with mitochondrial trifunctional protein disorders identified by newborn screening. Mol Genet Metab. 2010;101(2-3):205-207.
Wilcken B. Fatty acid oxidation disorders: outcome and long-term prognosis. J Inherit Metab Dis. 2010;33(5):501-506.
DaTorre SD, Creer MH, Pogwizd SM, et al. Amphipathic lipid metabolites and their relation to arrhythmogenesis in the ischemic heart. J Mol Cell Cardiol. 1991;23 Suppl 1:11-22.
Primassin, S., Ter Veld, F., Mayatepek, E. et al. Carnitine Supplementation Induces Acylcarnitine Production in Tissues of Very Long-Chain Acyl-CoA Dehydrogenase-Deficient Mice, Without Replenishing Low Free Carnitine. Pediatr Res. 2008;63, 632–637.
Derks TG, Reijngoud DJ, Waterham HR, et al. The natural history of mediumchain acyl CoA dehydrogenase deficiency in the Netherlands: clinical presentation and outcome. J Pediatr 2006;148:665–70.
Vishwanath VA. Fatty Acid Beta-Oxidation Disorders: A Brief Review. Ann Neurosci. 2016;23(1):51-55.
Merritt JL 2nd, Norris M, Kanungo S. Fatty acid oxidation disorders. Ann Transl Med. 2018;6(24):473.
Gallant NM, Leydiker K, Tang H, et al. Biochemical, molecular, and clinical characteristics of children with short chain acyl-CoA dehydrogenase deficiency detected by newborn screening in California. Mol Genet Metab 2012;106:55-61.
Olsen RK, Olpin SE, Andresen BS, et al. ETFDH mutations as a major cause of riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency. Brain 2007;130:2045-54.
